ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca, Bristol-Myers Squibb and AbbVie side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

AstraZeneca×Bristol-Myers Squibb×AbbVie×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaBristol-Myers SquibbAbbVie
studies on the registry4,1972,1842,251
open to participants now298155133
phase 3 studies under way2008274
reach primary completion within a year1686790
programswith a study of their own in two years119+5 named only57+9 named only70+8 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaBristol-Myers SquibbAbbVie
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Bristol-Myers Squibb: 17 of its 57 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

30%

AbbVie: 28 of its 70 programs at phase 1

  1. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1
  2. surzetoclaxphase 1
  3. BTK Degrader ABBV-101phase 1
  4. ABBV-1162phase 1
  5. ABBV-1451phase 1

and 23 more — sign in to see them all

40%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Bristol-Myers Squibb: 17 of its 57 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 12 more — sign in to see them all

30%

AbbVie: 20 of its 70 programs at phase 2

  1. ABBV-295phase 2
  2. zumilokibartphase 2
  3. ABBV-932phase 2
  4. trosunilimabphase 2
  5. ABBV-701phase 2

and 15 more — sign in to see them all

29%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Bristol-Myers Squibb: 16 of its 57 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%

AbbVie: 16 of its 70 programs at phase 3

  1. telisotuzumab adizutecanphase 3
  2. etentamigphase 3
  3. lutikizumabphase 3
  4. mirvetuximab soravtansinephase 3
  5. turmetabart adizutecanphase 3

and 11 more — sign in to see them all

23%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Bristol-Myers Squibb: 7 of its 57 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%

AbbVie: 6 of its 70 programs at approved, new studies

  1. upadacitinibapproved, new study
  2. risankizumabapproved, new study
  3. venetoclaxapproved, new study
  4. botulinum toxin type Aapproved, new study
  5. atogepantapproved, new study

and 1 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Bristol-Myers Squibb22 readouts · 7 phase 3

Bristol-Myers Squibb, Nov ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. trospiumapproved, new study · Nov 24 · NCT06585787
  2. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. navlimetostatphase 3 · Dec 5 · NCT07777133
  3. delocamtenphase 2 · Dec 14 · NCT06122779
  4. golcadomidephase 3 · Dec 14 · NCT07763418
  5. moponetugphase 2 · Dec 17 · NCT06268886

and 2 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836

Bristol-Myers Squibb, Mar ’27: 1 program whose next study reaches primary completion

  1. trospium chlorideapproved, new study · Mar 29 · NCT07063342
·

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
AbbVie34 readouts · 5 phase 3

AbbVie, Nov ’26: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-701phase 2 · Nov 0 · NCT06895343
  2. ABBV-932phase 2 · Nov 0 · NCT06846320
  3. mirvetuximab soravtansinephase 3 · Nov 0 · NCT05456685
  4. upadacitinibapproved, new study · Nov 0 · NCT06389136
  5. venetoclaxapproved, new study · Nov 0 · NCT04895436

and 1 more — sign in to see them all

AbbVie, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-295phase 2 · Dec 0 · NCT07514260
  2. emraclidinephase 2 · Dec 0 · NCT07219030
  3. lutikizumabphase 3 · Dec 0 · NCT06468228
  4. telisotuzumab adizutecanphase 3 · Dec 0 · NCT06107413

AbbVie, Jan ’27: 1 program whose next study reaches primary completion

  1. risankizumabapproved, new study · Jan 0 · NCT07466550

AbbVie, Feb ’27: 9 programs whose next study reaches primary completion

  1. [11C]ABBV-112iearly phase 1 · Feb 0 · NCT07933497
  2. ABBV-859phase 1 · Feb 0 · NCT07736638
  3. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1 · Feb 0 · NCT05512390
  4. etentamigphase 3 · Feb 0 · NCT06223516
  5. MEDI0618phase 2 · Feb 0 · NCT06602479

and 4 more — sign in to see them all

·

AbbVie, Apr ’27: 1 program whose next study reaches primary completion

  1. ABBV-1451phase 1 · Apr 0 · NCT07570147

AbbVie, May ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-1162phase 1 · May 0 · NCT07832708
  2. ABBV-243phase 1 · May 0 · NCT07306754
  3. ABBV-7828phase 1 · May 0 · NCT07856706
  4. Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969phase 1 · May 0 · NCT06318273
  5. trosunilimabphase 2 · May 0 · NCT07925983

and 1 more — sign in to see them all

AbbVie, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Jun 0 · NCT07794891

AbbVie, Jul ’27: 4 programs whose next study reaches primary completion

  1. ABBV-1606phase 1 · Jul 0 · NCT07935564
  2. azirkitugphase 1 · Jul 0 · NCT05005403
  3. surzetoclaxphase 2 · Jul 0 · NCT06291220
  4. surzetoclaxphase 1 · Jul 0 · NCT06291220

AbbVie, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. vedolizumabphase 3 · Aug 0 · NCT06880744

AbbVie, Sep ’27: 1 program whose next study reaches primary completion

  1. icalcaprantphase 2 · Sep 0 · NCT07276997
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

AbbVie

New programs 5

Reached a new phase 1

  • ABBV-722phase 3 · Oct 23 · Scleroderma, Systemic

Study stopped 0

None

Primary completion later 10

Where they overlap

Conditions where at least two of them have programs: 65 in all. A program counts in each condition its studies name most.

ConditionAstraZenecaBristol-Myers SquibbAbbVie
Carcinoma, Non-Small-Cell Lungall three · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Bristol-Myers Squibb in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. izalontamab brengitecanphase 3
  5. repotrectinibphase 3

and 6 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Non-Small-Cell Lung in search

AbbVie in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-1480phase 3
  3. azirkitugphase 1
  4. RC148no phase

Their studies: AbbVie’s studies of Carcinoma, Non-Small-Cell Lung in search

Prostatic Neoplasmsall three · compare here

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Bristol-Myers Squibb in Prostatic Neoplasms: 3 programs

  1. dezandrodegphase 3
  2. RYZ711phase 2
  3. orevandrodegphase 1

Their studies: Bristol-Myers Squibb’s studies of Prostatic Neoplasms in search

Breast Neoplasmsall three · compare here

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Bristol-Myers Squibb in Breast Neoplasms: 4 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. actinium AC-225 dotatatephase 3
  4. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Breast Neoplasms in search

AbbVie in Breast Neoplasms: 2 programs

  1. trifluridine tipiracil drug combinationphase 3
  2. RC148no phase

Their studies: AbbVie’s studies of Breast Neoplasms in search

Multiple Myelomaall three · compare here

Bristol-Myers Squibb in Multiple Myeloma: 6 programs

  1. mezigdomidephase 3
  2. arlocabtagene autoleucelphase 3
  3. Cyclophosphamidephase 2
  4. elranatamabphase 2
  5. fludarabinephase 1

and 1 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Multiple Myeloma in search

Neoplasmsall three · compare here

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Bristol-Myers Squibb in Neoplasms: 5 programs

  1. repotrectinibphase 3
  2. BMS-986488phase 1
  3. BMS-986500phase 1
  4. Digoxinphase 1
  5. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Neoplasms in search

Carcinoma, Hepatocellularall three · compare here

AstraZeneca in Carcinoma, Hepatocellular: 6 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. Leucovorinphase 2
  4. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2
  5. Ramucirumabphase 2

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Hepatocellular in search

Bristol-Myers Squibb in Carcinoma, Hepatocellular: 4 programs

  1. pumitamigphase 3
  2. Actinium Ac 225 GPC3-targeted Peptide RYZ801phase 2
  3. Nivolumabapproved, new study
  4. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Hepatocellular in search

AbbVie in Carcinoma, Hepatocellular: 1 program

  1. telisotuzumab adizutecanphase 3

Their studies: AbbVie’s studies of Carcinoma, Hepatocellular in search

Leukemia, Lymphocytic, Chronic, B-Cellall three · compare here

AstraZeneca in Leukemia, Lymphocytic, Chronic, B-Cell: 5 programs

  1. surovatamigphase 3
  2. ceralasertibphase 3
  3. monalizumabphase 3
  4. pirtobrutinibphase 2
  5. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Bristol-Myers Squibb in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. lisocabtagene maraleucelphase 3
  2. Cyclophosphamidephase 2
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

AbbVie in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. surzetoclaxphase 2
  2. surzetoclaxphase 1
  3. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Arthritis, Rheumatoidall three · compare here

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

Bristol-Myers Squibb in Arthritis, Rheumatoid: 3 programs

  1. tocilizumabphase 3
  2. BMS-986528phase 2
  3. BMS-986454phase 1

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Rheumatoid in search

AbbVie in Arthritis, Rheumatoid: 5 programs

  1. lutikizumabphase 3
  2. ABBV-722phase 3
  3. ravagalimabphase 2
  4. CPTX2309phase 1
  5. upadacitinibapproved, new study

Their studies: AbbVie’s studies of Arthritis, Rheumatoid in search

Stomach Neoplasmsall three · compare here

Bristol-Myers Squibb in Stomach Neoplasms: 1 program

  1. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Stomach Neoplasms in search

AbbVie in Stomach Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationphase 3

Their studies: AbbVie’s studies of Stomach Neoplasms in search

Crohn Diseaseall three · compare here

AstraZeneca in Crohn Disease: 1 program

  1. AZD7798phase 2

Their studies: AstraZeneca’s studies of Crohn Disease in search

Bristol-Myers Squibb in Crohn Disease: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Crohn Disease in search

AbbVie in Crohn Disease: 7 programs

  1. lutikizumabphase 3
  2. vedolizumabphase 3
  3. trosunilimabphase 2
  4. ABBV-701phase 2
  5. ABBV-8736phase 2

and 2 more — sign in to see them all

Their studies: AbbVie’s studies of Crohn Disease in search

Small Cell Lung Carcinomaall three · compare here

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

Bristol-Myers Squibb in Small Cell Lung Carcinoma: 5 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. atigotatugphase 3
  4. BMS-986525phase 2
  5. atigotatugphase 2

Their studies: Bristol-Myers Squibb’s studies of Small Cell Lung Carcinoma in search

Colorectal Neoplasmsall three · compare here

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Bristol-Myers Squibb in Colorectal Neoplasms: 3 programs

  1. pumitamigphase 3
  2. adagrasibphase 3
  3. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colorectal Neoplasms in search

AbbVie in Colorectal Neoplasms: 3 programs

  1. telisotuzumab adizutecanphase 3
  2. trifluridine tipiracil drug combinationphase 3
  3. RC148no phase

Their studies: AbbVie’s studies of Colorectal Neoplasms in search

Lupus Erythematosus, Systemicall three · compare here

Bristol-Myers Squibb in Lupus Erythematosus, Systemic: 3 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3
  3. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Lupus Erythematosus, Systemic in search

AbbVie in Lupus Erythematosus, Systemic: 1 program

  1. ABBV-519phase 1

Their studies: AbbVie’s studies of Lupus Erythematosus, Systemic in search

Colitis, Ulcerativeall three · compare here

AstraZeneca in Colitis, Ulcerative: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Colitis, Ulcerative in search

Bristol-Myers Squibb in Colitis, Ulcerative: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colitis, Ulcerative in search

AbbVie in Colitis, Ulcerative: 4 programs

  1. vedolizumabphase 3
  2. ravagalimabphase 2
  3. upadacitinibapproved, new study
  4. risankizumabapproved, new study

Their studies: AbbVie’s studies of Colitis, Ulcerative in search

Melanomaall three · compare here

AstraZeneca in Melanoma: 3 programs

  1. tremelimumabphase 3
  2. ceralasertibphase 3
  3. CD8-guided IL-2 Fusion Protein AZD6750phase 2

Their studies: AstraZeneca’s studies of Melanoma in search

Bristol-Myers Squibb in Melanoma: 2 programs

  1. Nivolumabapproved, new study
  2. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Melanoma in search

AbbVie in Melanoma: 1 program

  1. vedolizumabphase 3

Their studies: AbbVie’s studies of Melanoma in search

Obesityall three · compare here

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Bristol-Myers Squibb in Obesity: 1 program

  1. Digoxinphase 1

Their studies: Bristol-Myers Squibb’s studies of Obesity in search

AbbVie in Obesity: 1 program

  1. ABBV-295phase 2

Their studies: AbbVie’s studies of Obesity in search

Scleroderma, Systemicall three · compare here

AstraZeneca in Scleroderma, Systemic: 2 programs

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3
  2. anifrolumabapproved, new study

Their studies: AstraZeneca’s studies of Scleroderma, Systemic in search

Bristol-Myers Squibb in Scleroderma, Systemic: 2 programs

  1. zolacabtagene autoleucelphase 3
  2. tocilizumabphase 3

Their studies: Bristol-Myers Squibb’s studies of Scleroderma, Systemic in search

AbbVie in Scleroderma, Systemic: 1 program

  1. ABBV-722phase 3

Their studies: AbbVie’s studies of Scleroderma, Systemic in search

Lymphoma, Large B-Cell, Diffuseall three · compare here

AstraZeneca in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Large B-Cell, Diffuse in search

Bristol-Myers Squibb in Lymphoma, Large B-Cell, Diffuse: 2 programs

  1. lisocabtagene maraleucelphase 3
  2. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Large B-Cell, Diffuse in search

Idiopathic Pulmonary Fibrosisall three · compare here

AstraZeneca in Idiopathic Pulmonary Fibrosis: 1 program

  1. AZD8965phase 2

Their studies: AstraZeneca’s studies of Idiopathic Pulmonary Fibrosis in search

Bristol-Myers Squibb in Idiopathic Pulmonary Fibrosis: 1 program

  1. admilparantphase 3

Their studies: Bristol-Myers Squibb’s studies of Idiopathic Pulmonary Fibrosis in search

AbbVie in Idiopathic Pulmonary Fibrosis: 1 program

  1. ABBV-142phase 2

Their studies: AbbVie’s studies of Idiopathic Pulmonary Fibrosis in search

Asthma2 of 3 · compare here

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

–

AbbVie in Asthma: 1 program

  1. zumilokibartphase 2

Their studies: AbbVie’s studies of Asthma in search

Renal Insufficiency2 of 3 · compare here

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

–

AbbVie in Renal Insufficiency: 2 programs

  1. tavapadonphase 3
  2. emraclidinephase 2

Their studies: AbbVie’s studies of Renal Insufficiency in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Bristol-Myers Squibb in Pulmonary Disease, Chronic Obstructive: 1 program

  1. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Pulmonary Disease, Chronic Obstructive in search

–
Alzheimer Disease2 of 3 · compare here–

Bristol-Myers Squibb in Alzheimer Disease: 5 programs

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. xanomelineapproved, new study
  4. trospiumapproved, new study
  5. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Alzheimer Disease in search

AbbVie in Alzheimer Disease: 3 programs

  1. emraclidinephase 2
  2. ABBV-1758phase 2
  3. ALIA-1758phase 1

Their studies: AbbVie’s studies of Alzheimer Disease in search

Lymphoma, Follicular2 of 3 · compare here

AstraZeneca in Lymphoma, Follicular: 5 programs

  1. surovatamigphase 3
  2. camizestrantphase 3
  3. lenbelintidephase 3
  4. AZD9550phase 2
  5. AZD2389phase 2

Their studies: AstraZeneca’s studies of Lymphoma, Follicular in search

Bristol-Myers Squibb in Lymphoma, Follicular: 3 programs

  1. golcadomidephase 3
  2. lisocabtagene maraleucelphase 3
  3. repotrectinibphase 3

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Follicular in search

–
Heart Failure2 of 3 · compare here

AstraZeneca in Heart Failure: 6 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. balcinrenonephase 3
  4. Pexerelgonphase 2
  5. dapagliflozinapproved, new study

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Heart Failure in search

Bristol-Myers Squibb in Heart Failure: 1 program

  1. delocamtenphase 2

Their studies: Bristol-Myers Squibb’s studies of Heart Failure in search

–
Carcinoma, Renal Cell2 of 3 · compare here

AstraZeneca in Carcinoma, Renal Cell: 3 programs

  1. volrustomigphase 3
  2. Actinium-225phase 3
  3. casdatifanphase 1

Their studies: AstraZeneca’s studies of Carcinoma, Renal Cell in search

Bristol-Myers Squibb in Carcinoma, Renal Cell: 3 programs

  1. BMS-986527phase 1
  2. Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506phase 1
  3. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Renal Cell in search

–
Arthritis, Psoriatic2 of 3 · compare here–

Bristol-Myers Squibb in Arthritis, Psoriatic: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Psoriatic in search

AbbVie in Arthritis, Psoriatic: 4 programs

  1. lutikizumabphase 3
  2. ABBV-701phase 2
  3. ABBV-547phase 2
  4. risankizumabapproved, new study

Their studies: AbbVie’s studies of Arthritis, Psoriatic in search

Endometrial Neoplasms2 of 3 · compare here

AstraZeneca in Endometrial Neoplasms: 4 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. puxitatug samrotecanphase 3
  4. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Endometrial Neoplasms in search

–

AbbVie in Endometrial Neoplasms: 1 program

  1. opugotamig olatansinephase 2

Their studies: AbbVie’s studies of Endometrial Neoplasms in search

Neoplasm Metastasis2 of 3 · compare here

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Bristol-Myers Squibb in Neoplasm Metastasis: 2 programs

  1. adagrasibphase 3
  2. repotrectinibphase 3

Their studies: Bristol-Myers Squibb’s studies of Neoplasm Metastasis in search

–
Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here

AstraZeneca in Squamous Cell Carcinoma of Head and Neck: 3 programs

  1. tremelimumabphase 3
  2. volrustomigphase 3
  3. monalizumabphase 3

Their studies: AstraZeneca’s studies of Squamous Cell Carcinoma of Head and Neck in search

–

AbbVie in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-711phase 1

Their studies: AbbVie’s studies of Squamous Cell Carcinoma of Head and Neck in search

Triple Negative Breast Neoplasms2 of 3 · compare here

AstraZeneca in Triple Negative Breast Neoplasms: 4 programs

  1. datopotamab deruxtecanphase 3
  2. capivasertibphase 3
  3. ceralasertibphase 3
  4. Actinium-225phase 3

Their studies: AstraZeneca’s studies of Triple Negative Breast Neoplasms in search

Bristol-Myers Squibb in Triple Negative Breast Neoplasms: 1 program

  1. izalontamab brengitecanphase 3

Their studies: Bristol-Myers Squibb’s studies of Triple Negative Breast Neoplasms in search

–
Dermatitis, Atopic2 of 3 · compare here

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

–

AbbVie in Dermatitis, Atopic: 3 programs

  1. zumilokibartphase 2
  2. APG990phase 1
  3. upadacitinibapproved, new study

Their studies: AbbVie’s studies of Dermatitis, Atopic in search

Kidney Failure, Chronic2 of 3 · compare here

AstraZeneca in Kidney Failure, Chronic: 1 program

  1. Berzanoflastphase 2

Their studies: AstraZeneca’s studies of Kidney Failure, Chronic in search

Bristol-Myers Squibb in Kidney Failure, Chronic: 3 programs

  1. golcadomidephase 3
  2. admilparantphase 3
  3. mezigdomidephase 3

Their studies: Bristol-Myers Squibb’s studies of Kidney Failure, Chronic in search

–
Lymphoma2 of 3 · compare here

AstraZeneca in Lymphoma: 1 program

  1. PRMT5 Inhibitor AZD3470phase 2

Their studies: AstraZeneca’s studies of Lymphoma in search

Bristol-Myers Squibb in Lymphoma: 3 programs

  1. lisocabtagene maraleucelphase 3
  2. repotrectinibphase 3
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Lymphoma in search

–
Lymphoma, B-Cell2 of 3 · compare here

Bristol-Myers Squibb in Lymphoma, B-Cell: 1 program

  1. golcadomidephase 3

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, B-Cell in search

–
Lymphoma, Non-Hodgkin2 of 3 · compare here–

Bristol-Myers Squibb in Lymphoma, Non-Hodgkin: 3 programs

  1. golcadomidephase 3
  2. lisocabtagene maraleucelphase 3
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Non-Hodgkin in search

AbbVie in Lymphoma, Non-Hodgkin: 1 program

  1. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Lymphoma, Non-Hodgkin in search

Ovarian Neoplasms2 of 3 · compare here

AstraZeneca in Ovarian Neoplasms: 2 programs

  1. saruparibphase 3
  2. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Ovarian Neoplasms in search

–
Psoriasis2 of 3 · compare here–

Bristol-Myers Squibb in Psoriasis: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Psoriasis in search

AbbVie in Psoriasis: 3 programs

  1. ABBV-295phase 2
  2. ABBV-547phase 2
  3. risankizumabapproved, new study

Their studies: AbbVie’s studies of Psoriasis in search

Schizophrenia2 of 3 · compare here–

Bristol-Myers Squibb in Schizophrenia: 3 programs

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Schizophrenia in search

AbbVie in Schizophrenia: 1 program

  1. emraclidinephase 2

Their studies: AbbVie’s studies of Schizophrenia in search

Amyloidosis2 of 3 · compare here

AstraZeneca in Amyloidosis: 2 programs

  1. cliramitugphase 3
  2. acoramidisapproved, new study

Their studies: AstraZeneca’s studies of Amyloidosis in search

–

AbbVie in Amyloidosis: 1 program

  1. etentamigphase 3

Their studies: AbbVie’s studies of Amyloidosis in search

Anemia, Hemolytic, Autoimmune2 of 3 · compare here–

Bristol-Myers Squibb in Anemia, Hemolytic, Autoimmune: 2 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3

Their studies: Bristol-Myers Squibb’s studies of Anemia, Hemolytic, Autoimmune in search

AbbVie in Anemia, Hemolytic, Autoimmune: 1 program

  1. pegcetacoplanphase 2

Their studies: AbbVie’s studies of Anemia, Hemolytic, Autoimmune in search

Bipolar Disorder2 of 3 · compare here–

Bristol-Myers Squibb in Bipolar Disorder: 1 program

  1. Lithiumphase 1

Their studies: Bristol-Myers Squibb’s studies of Bipolar Disorder in search

AbbVie in Bipolar Disorder: 2 programs

  1. ABBV-932phase 2
  2. icalcaprantphase 2

Their studies: AbbVie’s studies of Bipolar Disorder in search

Colonic Neoplasms2 of 3 · compare here

AstraZeneca in Colonic Neoplasms: 2 programs

  1. oleclumabphase 3
  2. monalizumabphase 3

Their studies: AstraZeneca’s studies of Colonic Neoplasms in search

–

AbbVie in Colonic Neoplasms: 1 program

  1. RC148no phase

Their studies: AbbVie’s studies of Colonic Neoplasms in search

Depressive Disorder, Major2 of 3 · compare here–

Bristol-Myers Squibb in Depressive Disorder, Major: 1 program

  1. BMS-986511phase 2

Their studies: Bristol-Myers Squibb’s studies of Depressive Disorder, Major in search

AbbVie in Depressive Disorder, Major: 2 programs

  1. icalcaprantphase 2
  2. bretisilocinphase 2

Their studies: AbbVie’s studies of Depressive Disorder, Major in search

Fallopian Tube Neoplasms2 of 3 · compare here

AstraZeneca in Fallopian Tube Neoplasms: 1 program

  1. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Fallopian Tube Neoplasms in search

–

AbbVie in Fallopian Tube Neoplasms: 2 programs

  1. mirvetuximab soravtansinephase 3
  2. opugotamig olatansinephase 2

Their studies: AbbVie’s studies of Fallopian Tube Neoplasms in search

Hemoglobinuria, Paroxysmal2 of 3 · compare here

AstraZeneca in Hemoglobinuria, Paroxysmal: 2 programs

  1. ravulizumabapproved, new study
  2. eculizumabapproved, new study

Their studies: AstraZeneca’s studies of Hemoglobinuria, Paroxysmal in search

–

AbbVie in Hemoglobinuria, Paroxysmal: 1 program

  1. pegcetacoplanphase 2

Their studies: AbbVie’s studies of Hemoglobinuria, Paroxysmal in search

Liver Cirrhosis2 of 3 · compare here

AstraZeneca in Liver Cirrhosis: 2 programs

  1. zibotentanphase 3
  2. AZD2389phase 2

Their studies: AstraZeneca’s studies of Liver Cirrhosis in search

Bristol-Myers Squibb in Liver Cirrhosis: 1 program

  1. Digoxinphase 1

Their studies: Bristol-Myers Squibb’s studies of Liver Cirrhosis in search

–
Lupus Nephritis2 of 3 · compare here

AstraZeneca in Lupus Nephritis: 1 program

  1. anifrolumabapproved, new study

Their studies: AstraZeneca’s studies of Lupus Nephritis in search

Bristol-Myers Squibb in Lupus Nephritis: 2 programs

  1. zolacabtagene autoleucelphase 3
  2. BMS-986553phase 1

Their studies: Bristol-Myers Squibb’s studies of Lupus Nephritis in search

–
Lymphoma, Mantle-Cell2 of 3 · compare here

AstraZeneca in Lymphoma, Mantle-Cell: 2 programs

  1. pirtobrutinibphase 2
  2. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Mantle-Cell in search

–

AbbVie in Lymphoma, Mantle-Cell: 1 program

  1. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Lymphoma, Mantle-Cell in search

Multiple Sclerosis2 of 3 · compare here

Bristol-Myers Squibb in Multiple Sclerosis: 2 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3

Their studies: Bristol-Myers Squibb’s studies of Multiple Sclerosis in search

–
Pancreatic Neoplasms2 of 3 · compare here

AstraZeneca in Pancreatic Neoplasms: 2 programs

  1. sonesitatug vedotinphase 3
  2. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Pancreatic Neoplasms in search

Bristol-Myers Squibb in Pancreatic Neoplasms: 1 program

  1. navlimetostatphase 3

Their studies: Bristol-Myers Squibb’s studies of Pancreatic Neoplasms in search

–
Arthritis, Juvenile2 of 3 · compare here–

Bristol-Myers Squibb in Arthritis, Juvenile: 1 program

  1. tocilizumabphase 3

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Juvenile in search

AbbVie in Arthritis, Juvenile: 1 program

  1. risankizumabapproved, new study

Their studies: AbbVie’s studies of Arthritis, Juvenile in search

Carcinoma, Ovarian Epithelial2 of 3 · compare here

AstraZeneca in Carcinoma, Ovarian Epithelial: 1 program

  1. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Carcinoma, Ovarian Epithelial in search

–

AbbVie in Carcinoma, Ovarian Epithelial: 1 program

  1. mirvetuximab soravtansinephase 3

Their studies: AbbVie’s studies of Carcinoma, Ovarian Epithelial in search

COVID-192 of 3 · compare here

AstraZeneca in COVID-19: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of COVID-19 in search

Bristol-Myers Squibb in COVID-19: 1 program

  1. tocilizumabphase 3

Their studies: Bristol-Myers Squibb’s studies of COVID-19 in search

–
Hematologic Neoplasms2 of 3 · compare here

AstraZeneca in Hematologic Neoplasms: 1 program

  1. capivasertibphase 3

Their studies: AstraZeneca’s studies of Hematologic Neoplasms in search

–

AbbVie in Hematologic Neoplasms: 1 program

  1. BTK Degrader ABBV-101phase 1

Their studies: AbbVie’s studies of Hematologic Neoplasms in search

Kidney Diseases2 of 3 · compare here

AstraZeneca in Kidney Diseases: 1 program

  1. zibotentanphase 3

Their studies: AstraZeneca’s studies of Kidney Diseases in search

–

AbbVie in Kidney Diseases: 1 program

  1. trifluridine tipiracil drug combinationphase 3

Their studies: AbbVie’s studies of Kidney Diseases in search

Liver Diseases2 of 3 · compare here

AstraZeneca in Liver Diseases: 1 program

  1. AZD2389phase 2

Their studies: AstraZeneca’s studies of Liver Diseases in search

Bristol-Myers Squibb in Liver Diseases: 1 program

  1. admilparantphase 3

Their studies: Bristol-Myers Squibb’s studies of Liver Diseases in search

–
Lung Neoplasms2 of 3 · compare here

AstraZeneca in Lung Neoplasms: 1 program

  1. osimertinibapproved, new study

Their studies: AstraZeneca’s studies of Lung Neoplasms in search

Bristol-Myers Squibb in Lung Neoplasms: 1 program

  1. navlimetostatphase 3

Their studies: Bristol-Myers Squibb’s studies of Lung Neoplasms in search

–
Muscle Spasticity2 of 3 · compare here–

Bristol-Myers Squibb in Muscle Spasticity: 1 program

  1. irafamdastatphase 2

Their studies: Bristol-Myers Squibb’s studies of Muscle Spasticity in search

AbbVie in Muscle Spasticity: 1 program

  1. botulinum toxin type Aapproved, new study

Their studies: AbbVie’s studies of Muscle Spasticity in search

Overweight2 of 3 · compare here

AstraZeneca in Overweight: 1 program

  1. lenbelintidephase 3

Their studies: AstraZeneca’s studies of Overweight in search

–

AbbVie in Overweight: 1 program

  1. GUB014295phase 1

Their studies: AbbVie’s studies of Overweight in search

Precursor Cell Lymphoblastic Leukemia-Lymphoma2 of 3 · compare here

AstraZeneca in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. Menin Inhibitor AZD3632phase 2

Their studies: AstraZeneca’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

Bristol-Myers Squibb in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

–
Stroke2 of 3 · compare here–

Bristol-Myers Squibb in Stroke: 1 program

  1. milvexianphase 2

Their studies: Bristol-Myers Squibb’s studies of Stroke in search

AbbVie in Stroke: 1 program

  1. botulinum toxin type Aapproved, new study

Their studies: AbbVie’s studies of Stroke in search

Thrombosis2 of 3 · compare here

AstraZeneca in Thrombosis: 1 program

  1. andexanet alfaapproved, new study

Their studies: AstraZeneca’s studies of Thrombosis in search

Bristol-Myers Squibb in Thrombosis: 1 program

  1. milvexianphase 2

Their studies: Bristol-Myers Squibb’s studies of Thrombosis in search

–
Urinary Bladder, Overactive2 of 3 · compare here–

Bristol-Myers Squibb in Urinary Bladder, Overactive: 1 program

  1. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Urinary Bladder, Overactive in search

AbbVie in Urinary Bladder, Overactive: 1 program

  1. botulinum toxin type Aapproved, new study

Their studies: AbbVie’s studies of Urinary Bladder, Overactive in search

Uterine Cervical Neoplasms2 of 3 · compare here

AstraZeneca in Uterine Cervical Neoplasms: 1 program

  1. volrustomigphase 3

Their studies: AstraZeneca’s studies of Uterine Cervical Neoplasms in search

Bristol-Myers Squibb in Uterine Cervical Neoplasms: 1 program

  1. imzokitugphase 2

Their studies: Bristol-Myers Squibb’s studies of Uterine Cervical Neoplasms in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAstraZenecaBristol-Myers SquibbAbbVie
CD19Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, surovatamig, CT204V-CD19 × CD20ruleobexelimab, zolacabtagene autoleucel, lisocabtagene maraleucelruleABBV-519, Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31, CPTX2309
CD3Esurovatamig, Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492, Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863, Anti-GPC3 T Cell-engaging Antibody AZD9793, Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621elranatamabruleetentamig, Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001
TNFRSF17Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, Allogeneic Anti-BCMA CAR T-cells AZD4045tunlucabtagene autoleucel, elranatamabruleetentamig, Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001
PDCD1rilvegostomig, volrustomigatigotatug, NivolumabruleABBV-1480
GPC3Anti-GPC3 T Cell-engaging Antibody AZD9793Actinium Ac 225 GPC3-targeted Peptide RYZ801Anti-GPC3 Antibody-drug Conjugate ABBV-324
CHRM4–BMS-986521, xanomelineruleemraclidine, ABBV-1042
FOLR1torvutatug samrotecan–opugotamig olatansine, Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901, mirvetuximab soravtansinerule
BTKacalabrutinibrule, pirtobrutinibrule–BTK Degrader ABBV-101rule
C5eculizumabrule, ravulizumabrule–ABBV-6628
GPRC5Dvemzatatug vedotinarlocabtagene autoleucel, tunlucabtagene autoleucel–
KRASPan-KRAS Inhibitor JAB-23E73, AZD0240adagrasibrule–
VEGFA–pumitamigABBV-1480, surabgene lomparvovec
ARAndrogen Receptor Degrader AZD9750ruledezandrodegrule–
CCR8–imzokitugazirkitug
CD274durvalumabrulepumitamig–
EGFRosimertinibruleizalontamab brengitecan–
FOLH1zadavotide guraxetan–Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969
PRMT5PRMT5 Inhibitor AZD3470navlimetostat–
TYK2–deucravacitinibruleupadacitinibrule
A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · Bristol-Myers Squibb 32 of 57 · AbbVie 54 of 70 programs (57 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5, Bristol-Myers Squibb: 9, AbbVie: 8).